ADCAN Pharma, a UAE-based pharmaceutical manufacturer, has signed an agency agreement with Germany-based Pharma Resources GmbH at CPHI Milan 2026. The partnership aims to support ADCAN Pharma’s efforts to register its medicines in Germany, marking a step towards expanding UAE-manufactured pharmaceutical products into European markets.
The agreement will combine ADCAN Pharma’s manufacturing capabilities with Pharma Resources’ regulatory expertise and knowledge of the German market. It is also expected to support preparations for an EU Good Manufacturing Practice (EU GMP) inspection and certification process by German authorities.
Click here to join our WhatsApp channel here
Dr Shaikha Al Mazrouei, Research and Studies Advisor at the Emirates Drug Establishment (EDE), said: “The move toward registering UAE-manufactured pharmaceutical products in a highly regulated market such as Germany is an important indicator of the development of national manufacturing capabilities and their readiness to compete globally. At the Emirates Drug Establishment, we are committed to strengthening regulatory frameworks aligned with global best practices, advancing quality and compliance, and supporting national manufacturers in meeting international requirements and expanding the global reach of UAE-manufactured medicines.”
ADCAN Pharma leadership described the agreement as part of the UAE’s broader ambition to strengthen domestic manufacturing and compete in international markets. The company said that meeting European quality and regulatory requirements would help establish its position as an export-ready pharmaceutical manufacturer.
Dr Fokion Sinis, Chief Executive Officer, ADCAN Pharma, added: ” This important milestone will pave the way for the EU GMP inspection and certification process by the German authorities. This is about more than regulatory compliance — it’s about proving that UAE-manufactured medicines can compete and succeed on the global stage. This partnership with Pharma Resources is a strategic gateway to European markets, and it reflects our long-term vision to make ADCAN a trusted name in international pharmaceutical manufacturing.”
Pharma Resources will provide regulatory guidance to help ADCAN Pharma navigate European product registration requirements and compliance obligations. Both companies highlighted the importance of quality standards, patient safety and a clear understanding of the European Union’s pharmaceutical regulatory framework.
Dr Adel Merzekani, Chief Operating Officer, ADCAN Pharma elaborated ” This breakthrough will support ADCAN’s ambition to enter the European market. Achieving EU GMP certification would represent a major recognition of our manufacturing and quality standards as it is widely regarded as one of the most rigorous quality benchmarks in global pharmaceutical manufacturing. It also positions ADCAN more broadly, as a credible, export-ready manufacturing hub rather than solely a domestic supplier.”
Also read: “Stronger in Pink” Campaign Promotes Women’s Health and Early Detection
Juliana Dodillet, Managing Director, Pharma Resources GmbH said “We are delighted to partner with ADCAN Pharma in this important step toward the European market. Entering highly regulated markets such as Germany requires a strong commitment to quality, compliance, and patient safety. ADCAN Pharma has demonstrated a clear ambition to meet international standards and to expand its global footprint. “
“This partnership represents an important step toward establishing ADCAN Pharma’s presence in the European pharmaceutical market. Successful entry into Europe requires not only high-quality products but also a comprehensive understanding of the regulatory framework and lifecycle requirements governing medicinal products within the European Union. At Pharma Resources GmbH, we are committed to supporting ADCAN Pharma throughout this journey by providing regulatory expertise and strategic guidance. We look forward to working closely together to facilitate product registrations and ensure compliance with European regulatory standards.” added Hans-Günter Beck, Head of Regulatory Affairs & QPPV
The Emirates Drug Establishment also emphasised its commitment to strengthening regulatory systems and supporting UAE manufacturers in meeting international quality requirements. The partnership aligns with the country’s “Made in the UAE” vision and its goal of developing the UAE into a regional hub for pharmaceutical manufacturing and life sciences.
